Clinical trials: Gastrointestinal Reflux
Gastroesophageal Reflux Disease (GERD)
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who are partial-responders to PPI…
- Trial name
- REMAIN (NCT00795093)
- Where
- 53 sites in United States
- Volunteers
- 552 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Mass Balance Study of [14C]X842 in Healthy Adult Male Subjects
This study is a single-site, single-dose, non-randomized, open-label study to assess the absorption, metabolism, and excretion profile of [14C]X842 in healthy adult male subjects.
- Trial name
- NCT07107672
- Testing
- [14C]X842
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Reflux Esophagitis (RE)
A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
This Phase III clinical trial is designed to assess the efficacy and safety of Anaprazole 60 mg once daily (QD) administered over a period of up to 8 weeks, compared with Rabeprazole 20 mg QD, in patients with reflux esophagitis.
- Trial name
- NCT07010107
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Pulmonary Regurgitation, Pulmonary Insufficiency
Pulmonic Valve REplacement Multi-discIpline EMEA Registry
The purpose of this registry is to retrospectively and prospectively obtain clinical data in consecutively treated patients, in order to demonstrate that the commercially available Edwards SAPIEN Valve with the RF3 delivery…
- Conditions
- Pulmonary Regurgitation, Pulmonary Insufficiency, Pulmonary Stenosis
- Trial name
- PREMIER (NCT01356108)
- Testing
- Transcatheter Pulmonic Valve Replacement (TPVR) (Edwards SAPIEN™ THV)
- Where
- 16 sites in Belgium, Germany and 7 more
- Volunteers
- 127 people
- Sponsor
- Edwards Lifesciences
Non Erosive Reflux Disease
S-pantoprazole 10mg Phase III Clinical Study
This clinical study hypothesized that S-pantoprazole 10mg would be effective to treat Non erosive Reflux Disease than placebo.
- Trial name
- NCT02274961
- Testing
- S-pantoprazole 10mg
- Where
- 10 sites in South Korea
- Volunteers
- 174 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Symptomatic Gastroesophageal Reflux Disease (sGERD)
Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)
The purpose of this study is to compare the efficacy, safety and tolerability of rabeprazole extended release (ER) 50 mg with placebo in subjects with symptomatic gastroesophageal reflux disease (sGERD).
- Trial name
- NCT00911534
- Testing
- rabeprazole sodium
- Where
- 98 sites in United States
- Volunteers
- 305 people
- Sponsor
- Eisai Inc.
Dyspepsia
The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.
"Functional dyspepsia" has been defined loosely as "pain or discomfort centered in the upper abdomen." The symptoms can also include fullness, early satiety, bloating, belching, nausea, retching and vomiting.
- Trial name
- NCT00303264
- Testing
- dexloxiglumide, Nexium (esomeprazole)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Forest Laboratories
GERD (Heartburn, Regurgitation, and Dyspepsia), Gastroesophageal Reflux (GERD)
A Pre-market, Two-stages Interventional Clinical Investigation to Evaluate the Safety and the Performance of Fibroin Syrup in Reducing the Gastroesophageal Reflux Disease (GERD) Symptomatology in Nonerosive Reflux Disease (NERD) Patients
This study involves a medical device in the form of syrup, not yet on the market and tested for the first time in humans, named "FIBROIN SYRUP".
- Trial name
- NCT07563790
- Testing
- Syrup made by hyaluronic acid
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- Rose Pharma SA
Tricuspid Valve Regurgitation, Heart Valve Diseases
2019-06 TRISCEND Study
Prospective, multi-center study to assess safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System
- Conditions
- Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
- Trial name
- NCT04221490
- Testing
- Transcatheter Tricuspid Valve Replacement
- Where
- 20 sites in United States, Canada and 2 more
- Volunteers
- 228 people
- Sponsor
- Edwards Lifesciences
GERD
Registry Study of the NDO Surgical Plicator for the Treatment of GERD
The purpose of this study is to collect post-marketing data on patient outcomes and satisfaction following treatment with the Plicator™.
- Trial name
- NCT00597792
- Testing
- NDO Full-thickness Plicator
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NDO Surgical, Inc.
Gastroesophageal Reflux Disease (GERD), Peptic Ulcers
Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD might occur when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Trial name
- NCT00261300
- Testing
- Pantoprazole
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Takeda
GERD
LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
Evaluate burden of disease in Patients with newly occurred upper GI symptoms related to GERD (symptom frequency \& severity, QoL, lifestyle modifications, self-medication) - baseline data according to GERD impact scale presenting…
- Trial name
- NCT00567619
- Where
- Austria
- Volunteers
- 900 people
- Sponsor
- AstraZeneca
GERD
A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects
A randomized, open-label, multiple-dose crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult…
- Trial name
- NCT06141577
- Testing
- UI059, UIC202201
- Where
- South Korea
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn
The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn…
- Trial name
- NCT00251758
- Testing
- Dexlansoprazole MR
- Where
- 99 sites in United States
- Volunteers
- 908 people
- Sponsor
- Takeda
Esophagitis, Reflux
Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis
STU-Na belongs to the proton pump inhibitors (PPI), a group of drugs that reduce gastric acidity. PPI are used to treat acid related diseases like erosive or ulcerative esophagitis.
- Trial name
- NCT00282555
- Testing
- S-Tenatoprazole-Na (STU-Na)
- Where
- 17 sites in Canada
- Volunteers
- 450 people
- Sponsor
- STEBA France
Gastroesophageal Reflux
Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Trial name
- NCT00246909
- Testing
- Pantoprazole
- Where
- 51 sites in United States
- Volunteers
- 600 people
- Sponsor
- Takeda